Sunday, November 8, 2026

EUR/CHF Over 1% Up In The Last 10 Sessions

EUR/CHF Over 1% Up In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.73% for the last 10 sessions. At 23:06 EST on Wednesday, 3 July, EUR/CHF (EURCHF) is $0.97.

EUR/CHF's yearly highs and lows, it's 7.608% up from its 52-week low and 2.145% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • According to FXStreet on Tuesday, 2 July, "At the time of writing, EUR/USD is dropping 0.18% on the day to trade near 1.0720."
  • According to FXStreet on Wednesday, 3 July, "After hitting a low of 1.0666 towards the end of last month, EUR/USD initially jumped to a high of 1.0776 on Monday after the release of results from the first round of the French elections triggered a relief rally for EUR, the pair has since fallen back towards the 1.0700-level and recovered back to 1.0800."
  • Eur/usd carries a heavy weighting within DXY – rabobank. According to FXStreet on Wednesday, 3 July, "Despite the uncertainties connected with the French election, the EUR/USD is trading slightly above its mid-June levels as the market reacts to an increase in expectations that Le Pen's far-right party will fail to win an outright parliamentary majority in Sunday's run-off election."
  • Eur/usd: last day in sintra – ING. According to FXStreet on Wednesday, 3 July, "While a softer USD coulddrive EUR/USD above 1.0800, we doubt there is enough steam to rise to 1.0900 for now."

More news about EUR/CHF (EURCHF).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com